Compare Quest Diagnostics Inc (DGX) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hut 8 Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Hut 8 Corp trades at $84.27 (market cap $9.82B). The key difference: Quest Diagnostics Inc is far larger — about 2.6× Hut 8 Corp's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Hut 8 Corp for 11 Days on average.
| DGX | HUT | |
|---|---|---|
Market Cap | $25.48B | $9.82B |
Volume | 941,866 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $247.45 | $133.02 |
52-Week Low | $173.49 | $33.76 |
Typical Hold Time | 56 Days | 11 Days |
Enterprise Value | $31.23B | $17.25B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
HUT trades at $79.59, down 10.87% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -188.59% net income margin and has missed earnings expectations for three consecutive quarters. Recent positive developments include securing a $1.07 billion credit facility and growing institutional interest, positioning the company in the expanding AI infrastructure market.
While analyst consensus remains strongly bullish with a $162.69 price target, significant risks persist including ongoing losses, high valuation multiples, and competitive pressures in AI infrastructure. The stock's outlook hinges on successful execution of its business transformation and achieving profitability amid substantial capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
